	US 12,121,566 B2
	Methods for treating gout
Jeffrey D. Kent, Deerfield, IL (US); and Brian Lamoreaux, Lake Forest, IL (US)
Assigned to Horizon Therapeutics USA, Inc., Deerfield, IL (US)
Filed by Horizon Therapeutics USA, Inc., Deerfield, IL (US)
Filed on Jan. 30, 2020, as Appl. No. 16/777,625.
Claims priority of provisional application 62/903,562, filed on Sep. 20, 2019.
Claims priority of provisional application 62/798,782, filed on Jan. 30, 2019.
Prior Publication US 2020/0237879 A1, Jul. 30, 2020
Int. Cl. A61K 38/44 (2006.01); A61K 9/00 (2006.01); A61K 31/52 (2006.01); A61P 19/06 (2006.01)

CPC A61K 38/44 (2013.01) [A61K 9/0053 (2013.01); A61K 31/52 (2013.01); A61P 19/06 (2018.01)]

16 Claims

1. A method of treating gout in a patient, the method comprising administering a PEGylated uricase and azathioprine (AZA) to the patient; wherein the PEGylated uricase is administered weekly for a total of 3 weeks at a dose of 8 mg protein and then administered bi-weekly at a dose of 8 mg protein, wherein the AZA is dosed at about 1.25-5.5 mg/kg daily.